These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 35850175)
1. Antileukemic effects of topoisomerase I inhibitors mediated by de-SUMOylase SENP1. Niu Q; Hou W; Yan Y; Sun S; Lin Y; Fang H; Ma C; Dong C; Cheng Y; Xu Y; Ding M; Wang S; Cui Z; Chen Y; Li H; Li H; Xiao N Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166492. PubMed ID: 35850175 [TBL] [Abstract][Full Text] [Related]
2. SENP1 participates in Irinotecan resistance in human colon cancer cells. Chen MC; Nhan DC; Hsu CH; Wang TF; Li CC; Ho TJ; Mahalakshmi B; Chen MC; Yang LY; Huang CY J Cell Biochem; 2021 Oct; 122(10):1277-1294. PubMed ID: 34037277 [TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2. Wen D; Xiao H; Gao Y; Zeng H; Deng J Mol Cancer; 2024 May; 23(1):116. PubMed ID: 38822351 [TBL] [Abstract][Full Text] [Related]
4. SENP1 participates in the dynamic regulation of Elk-1 SUMOylation. Witty J; Aguilar-Martinez E; Sharrocks AD Biochem J; 2010 May; 428(2):247-54. PubMed ID: 20337593 [TBL] [Abstract][Full Text] [Related]
5. Sumoylation Negatively Regulates CSR1-Dependent Prostate Cancer Cell Death. Luo HR; Liu Y; Wan XD; Li JL; Wu M; Zhang QM; Wu DL; Zhao X; Wang TR Cell Physiol Biochem; 2018; 46(5):1861-1867. PubMed ID: 29705808 [TBL] [Abstract][Full Text] [Related]
6. SENP1-mediated NEMO de-SUMOylation inhibits intermittent hypoxia induced inflammatory response of microglia in vitro. Yang T; Sun J; Wei B; Liu S J Cell Physiol; 2020 Apr; 235(4):3529-3538. PubMed ID: 31549402 [TBL] [Abstract][Full Text] [Related]
7. SENP1 modulates microglia-mediated neuroinflammation toward intermittent hypoxia-induced cognitive decline through the de-SUMOylation of NEMO. Wang H; Yang T; Sun J; Zhang S; Liu S J Cell Mol Med; 2021 Jul; 25(14):6841-6854. PubMed ID: 34120412 [TBL] [Abstract][Full Text] [Related]
8. SUMOylation protects against IL-1β-induced apoptosis in INS-1 832/13 cells and human islets. Hajmrle C; Ferdaoussi M; Plummer G; Spigelman AF; Lai K; Manning Fox JE; MacDonald PE Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E664-73. PubMed ID: 25139051 [TBL] [Abstract][Full Text] [Related]
9. Genetic Polymorphism of SUMO-Specific Cysteine Proteases - SENP1 and SENP2 in Breast Cancer. Mirecka A; Morawiec Z; Wozniak K Pathol Oncol Res; 2016 Oct; 22(4):817-23. PubMed ID: 27178176 [TBL] [Abstract][Full Text] [Related]
10. MYB regulates the SUMO protease SENP1 and its novel interaction partner UXT, modulating MYB target genes and the SUMO landscape. Lemma RB; Ledsaak M; Fuglerud BM; Rodríguez-Castañeda F; Eskeland R; Gabrielsen OS J Biol Chem; 2023 Sep; 299(9):105062. PubMed ID: 37468105 [TBL] [Abstract][Full Text] [Related]
11. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Tomicic MT; Kaina B Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513 [TBL] [Abstract][Full Text] [Related]
12. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Kaikkonen S; Jääskeläinen T; Karvonen U; Rytinki MM; Makkonen H; Gioeli D; Paschal BM; Palvimo JJ Mol Endocrinol; 2009 Mar; 23(3):292-307. PubMed ID: 19116244 [TBL] [Abstract][Full Text] [Related]
13. SENP1 modulates chronic intermittent hypoxia-induced inflammation of microglia and neuronal injury by inhibiting TOM1 pathway. Wang H; Wang X; Shen Y; Wang Y; Yang T; Sun J; Liu S Int Immunopharmacol; 2023 Jun; 119():110230. PubMed ID: 37137262 [TBL] [Abstract][Full Text] [Related]
14. Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Wu J; Lei H; Zhang J; Chen X; Tang C; Wang W; Xu H; Xiao W; Gu W; Wu Y Oncotarget; 2016 Sep; 7(37):58995-59005. PubMed ID: 27449295 [TBL] [Abstract][Full Text] [Related]
15. The SUMO-specific protease SENP1 deSUMOylates p53 and regulates its activity. Chauhan KM; Chen Y; Chen Y; Liu AT; Sun XX; Dai MS J Cell Biochem; 2021 Feb; 122(2):189-197. PubMed ID: 32786121 [TBL] [Abstract][Full Text] [Related]
16. Glucose Oxidase- and UVA-Induced Changes in the Expression Patterns of Seven De-sumoylation Enzymes (SENPs) Are Associated with Cataract Development. Xiang JW; Xiao Y; Gan Y; Chen H; Liu Y; Wang L; Nie Q; Liu F; Gong X; Fu JL; Qing WJ; Yang L; Xie J; Luo Z; Qi R; Chen Z; Li DW Curr Mol Med; 2019; 19(1):48-53. PubMed ID: 30854967 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of SENP1 inhibits cell proliferation, migration and promotes apoptosis in human glioma cells. Zhang QS; Zhang M; Huang XJ; Liu XJ; Li WP Oncol Lett; 2016 Jul; 12(1):217-221. PubMed ID: 27347128 [TBL] [Abstract][Full Text] [Related]
18. Computational drug repurposing of bethanidine for SENP1 inhibition in cardiovascular diseases treatment. Taghvaei S; Minuchehr Z; Sabouni F Life Sci; 2022 Mar; 292():120122. PubMed ID: 34748762 [TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401 [TBL] [Abstract][Full Text] [Related]
20. Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia. Wang FF; Liu MZ; Sui Y; Cao Q; Yan B; Jin ML; Mo X Oncol Lett; 2016 Nov; 12(5):3755-3762. PubMed ID: 27895727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]